KEGG   DRUG: Bevacizumab
Entry
D06409                      Drug                                   
Name
Bevacizumab (USAN);
Bevacizumab (genetical recombination) (JAN);
Bevacizumab (genetical recombination) [Bevacizumab biosimilar 1] (JAN);
Bevacizumab (genetical recombination) [Bevacizumab biosimilar 2] (JAN);
Bevacizumab (genetical recombination) [Bevacizumab biosimilar 3] (JAN);
Bevacizumab (genetical recombination) [Bevacizumab biosimilar 4] (JAN);
Bevacizumab-awwb;
Bevacizumab-bvzr;
Bevacizumab-maly;
Bevacizumab-adcd;
Bevacizumab-tnjn;
Avastin (TN);
Alymsys (TN);
Mvasi (TN);
Vegzelma (TN);
Zirabev (TN)
Product
ALYMSYS (Amneal Pharmaceuticals LLC), AVASTIN (Genentech), AVZIVI (Bio-Thera Solutions), MVASI (Amgen), VEGZELMA (CELLTRION USA), ZIRABEV (Pfizer Laboratories Div Pfizer)
Formula
C6638H10160N1720O2108S44
Exact mass
149104.8408
Mol weight
149196.88
Remark
Therapeutic category: 4291
ATC code: L01FG01 S01LA08
Product: D06409<JP/US>
Efficacy
Antineoplastic, Angiogenesis inhibitor, Anti-VEGF antibody
  Disease
Colorectal cancer [DS:H00020]
Non-squamous non-small cell lung cancer [DS:H00014]
Glioblastoma [DS:H00042]
Renal cell carcinoma [DS:H00021]
Cervical cancer [DS:H00030]
Epithelial ovarian cancer [DS:H00027]
Fallopian tube cancer [DS:H01554]
Primary peritoneal cancer [DS:H01665]
Hepatocellular carcinoma [DS:H00048]
  Type
Monoclonal antibody
Target
VEGFA [HSA:7422] [KO:K05448]
  Pathway
hsa04370  VEGF signaling pathway
hsa05200  Pathways in cancer
hsa05211  Renal cell carcinoma
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    L01FG VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors
     L01FG01 Bevacizumab
      D06409  Bevacizumab (USAN) <JP/US>
 S SENSORY ORGANS
  S01 OPHTHALMOLOGICALS
   S01L OCULAR VASCULAR DISORDER AGENTS
    S01LA Antineovascularisation agents
     S01LA08 Bevacizumab
      D06409  Bevacizumab (USAN) <JP/US>
USP drug classification [BR:br08302]
 Antineoplastics
  Monoclonal Antibody/Antibody-Drug Conjugate
   Anti-VEGF Antibodies
    Bevacizumab
     D06409  Bevacizumab (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D06409  Bevacizumab (USAN); Bevacizumab (genetical recombination) (JAN); Bevacizumab (genetical recombination) [Bevacizumab biosimilar 1] (JAN); Bevacizumab (genetical recombination) [Bevacizumab biosimilar 2] (JAN); Bevacizumab (genetical recombination) [Bevacizumab biosimilar 3] (JAN); Bevacizumab (genetical recombination) [Bevacizumab biosimilar 4] (JAN)
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokines
   Growth factors (RTK-binding)
    VEGFA
     D06409  Bevacizumab (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D06409
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D06409
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D06409
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D06409
Other DBs
CAS: 216974-75-3
PubChem: 47208066
NIKKAJI: J2.239.973J
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system